TY - JOUR
T1 - Detection of antiphospholipid antibodies by automated chemiluminescence assay
AU - Capozzi, Antonella
AU - Lococo, Emanuela
AU - Grasso, Maria
AU - Longo, Agostina
AU - Garofalo, Tina
AU - Misasi, Roberta
AU - Sorice, Maurizio
PY - 2012/5/31
Y1 - 2012/5/31
N2 - The laboratory diagnosis of antiphospholipid antibody syndrome (APS) requires the demonstration of antiphospholipid antibodies (aPL) by lupus anticoagulant (LAC) measured through coagulation assays, anticardiolipin IgG or IgM antibodies (aCL) and/or anti-β2-glycoprotein I IgG or IgM antibodies (anti-β2-GPI), usually detected by ELISA.In this study we tested aCL by a new automated system using the chemiluminescence principle.Our results showed that, while almost all the sera from APS patients, positive for IgG aCL and anti-β2-GPI by ELISA, were also positive for IgG aCl by chemiluminescence, only 30.13% of patients without clinical manifestations of APS, but positive for aCL and persistently negative for anti-β2-GPI (by ELISA) and LA, confirmed the positive test by chemiluminescence. This difference was highly significant (p<0.0001). Interestingly, this test also prompted to identify 20% of patients positive for LA, but persistently negative for both aCL and anti-β2-GPI IgG (ELISA).Thus, the new technology of automated chemiluminescence assay for measuring aPL may represent an useful tool to identify "true" APS patients.
AB - The laboratory diagnosis of antiphospholipid antibody syndrome (APS) requires the demonstration of antiphospholipid antibodies (aPL) by lupus anticoagulant (LAC) measured through coagulation assays, anticardiolipin IgG or IgM antibodies (aCL) and/or anti-β2-glycoprotein I IgG or IgM antibodies (anti-β2-GPI), usually detected by ELISA.In this study we tested aCL by a new automated system using the chemiluminescence principle.Our results showed that, while almost all the sera from APS patients, positive for IgG aCL and anti-β2-GPI by ELISA, were also positive for IgG aCl by chemiluminescence, only 30.13% of patients without clinical manifestations of APS, but positive for aCL and persistently negative for anti-β2-GPI (by ELISA) and LA, confirmed the positive test by chemiluminescence. This difference was highly significant (p<0.0001). Interestingly, this test also prompted to identify 20% of patients positive for LA, but persistently negative for both aCL and anti-β2-GPI IgG (ELISA).Thus, the new technology of automated chemiluminescence assay for measuring aPL may represent an useful tool to identify "true" APS patients.
KW - Anti-beta2 glycoprotein I antibodies
KW - Anticardiolipin antibodies
KW - Antiphospholipid syndrome
KW - Lupus anticoagulant
KW - Thrombosis
KW - Zenit RA analyzer
UR - http://www.scopus.com/inward/record.url?scp=84859751592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859751592&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2012.02.020
DO - 10.1016/j.jim.2012.02.020
M3 - Article
C2 - 22421684
AN - SCOPUS:84859751592
VL - 379
SP - 48
EP - 52
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
SN - 0022-1759
IS - 1-2
ER -